Expression level of histone deacetylase 2 correlates with occurring of chronic obstructive pulmonary diseases

Molecular Biology Reports

Volumn 40, Issue 6, 2013, Pages 3995-4000

  Qu, Yiqing ^a   Yang, Yie ^b   Ma, Dedong ^a   He, Liangai ^a   Xiao, Wei ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Biomarkers; COPD; HDAC proteins

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 5; MESSENGER RNA;

ADULT; AGED; ARTICLE; BRONCHUS MUCOSA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PROGNOSIS; PROTEIN EXPRESSION; SMOKING;

AGED; BRONCHI; CASE-CONTROL STUDIES; CELL LINE; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTONE DEACETYLASE 2; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RNA, MESSENGER; SMOKING;

EID: 84877724839     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2477-z     Document Type: Article

References (31)

1. Barnes PJ (2000) Chronic obstructive pulmonary disease. New Engl J Med 343:269-280
2. Rabe KF, Hurd S, Anzueto A et al (2007) Global strategy for the diagnosis, management, and prevention of COPD. Am J Respir Crit Care Med 176:532-555
3. Barnes PJ (2007) Chronic obstructive pulmonary disease: a growing but neglected epidemic. PLoS Med 4:e112
4. Grabiec AM, Tak PP, Reedquist KA (2011) Function of histone deacetylase inhibitors in inflammation. Crit Rev Immunol 31:233-263
5. Kersul AL, Iglesias A, Ríos Á et al (2011) Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 47:176-183
6. Urnov FD, Wolffe AP (2001) Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene 20:2991-3006
7. Blanchard F, Chipoy C (2005) Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov 10:197-204
8. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51
9. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ (2011) Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 32:335-343
10. Vojinovic J, Damjanov N (2011) HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol Med 17:397-403
11. Müller S, Krämer OH (2010) Inhibitors of HDACs-effective drugs against cancer? Curr Cancer Drug Targets 10:210-228
12. Glozak MA, Sengupta N, Zhang X, Seto E (2005) Acetylation and deacetylation of non-histone proteins. Gene 363:15-23
13. Li D, Marchenko ND, Moll UM (2011) SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 18:1904-1913
14. Bansal N, Kadamb R, Mittal S, Vig L, Sharma R, Dwarakanath BS, Saluja D (2011) Tumor suppressor protein p53 recruits human Sin3B/HDAC1 complex for down-regulation of its target promoters in response to genotoxic stress. PLoS ONE 6:e26156
15. Chen Y, Wang H, Yoon SO et al (2011) HDAC-mediated deacetylation of NF-κB is critical for Schwann cell myelination. Nat Neurosci 14:437-441
16. Bendinelli P, Matteucci E, Maroni P, Desiderio MA (2009) NF-kappaB activation, dependent on acetylation/deacetylation, contributes to HIF-1 activity and migration of bone metastatic breast carcinoma cells. Mol Cancer Res 7:1328-1341
17. Hsu YF, Sheu JR, Lin CH, Chen WC, Hsiao G, Ou G, Chiu PT, Hsu MJ (2011) MAPK phosphatase-1 contributes to trichostatin A inhibition of cyclooxygenase-2 expression in human umbilical vascular endothelial cells exposed to lipopolysaccharide. Biochim Biophys Acta 1810:1160-1169
18. Hogg JC, Chu F, Utokaparch S et al (2004) The nature of smallairway obstruction in chronic obstructive pulmonary disease. New Engl J Med 350:2645-2653
19. Ha MK, Song YH, Jeong SJ et al (2011) Emodin inhibits proinflammatory responses and inactivates histone deacetylase 1 in hypoxic rheumatoid synoviocytes. Biol Pharm Bull 34:1432-1437
20. Patel IS, Roberts NJ, Lloyd-Owen SJ, Sapsford RJ, Wedzicha JA (2003) Airway epithelial inflammatory responses and clinical parameters in COPD. Eur Respir J 22:94-99
21. Hogg JC (2004) Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364:709-721
22. Barnes PJ, Adcock IM, Ito K (2005) Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 25:552-563
23. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737-749
24. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF (2003) Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 983:84-100
25. Weerasinghe SV, Wambua M, Pflum MK (2010) A histone deacetylase-dependent screen in yeast. Bioorg Med Chem 18:7586-7592
26. Ehrentraut S, Weber JM, Dybowski JN, Hoffmann D, Ehrenhofer-Murray AE (2010) Rpd3-dependent boundary formation at telomeres by removal of Sir2 substrate. Proc Natl Acad Sci U S A 107:5522-5527
27. Yang XJ, Seto E (2008) The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 9:206-218
28. Choy JS, Acuña R, Au WC, Basrai MA (2011) A role for histone H4K16 hypoacetylation in Saccharomyces cerevisiae kinetochore function. Genetics 189:11-21
29. Marwick JA, Kirkham PA, Stevenson CS et al (2004) Cigarette smoke alters chromatin remodelling and induces proinflammatory genes in rat lungs. Am J Respir Cell Mol Biol 31:633-642
30. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM (2001) Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 15:1100-1102
31. Kim DR, Park MY, Lee CS et al (2011) Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells. Cancer Gene Ther 18:467-477